+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery



Optimizing classification of drug-drug interaction potential for CYP450 isoenzyme inhibition assays in early drug discovery



Journal of Biomolecular Screening 12(1): 92-99



In drug discovery, the potential of cytochrome P450 inhibition of new chemical entities is frequently quantified in terms of IC50 values. In early drug discovery, a risk classification into low, medium, or high potential inhibitors is often sufficient for ranking and prioritizing of compounds. Although often 6 or more inhibitor concentrations are used to determine the IC50 value, the question arises whether it is possible to predict the risk class based on fewer inhibitor concentrations with comparable reliability. In this article, the authors propose a new integrated 2-point method with inhibitor concentrations chosen in accordance with the risk classification. They analyze its predictive power and the feasibility of not only classifying the compounds into different risk classes but also ranking those compounds that have been binned into the middle risk class. The proposed integrated 2-point method is thus highly suitable for automation. Altogether, it maintains the quality of the prediction while considerably reducing time and cost. The proposed method is applicable to other IC50 assays and risk classifications.

(PDF emailed within 0-6 h: $19.90)

Accession: 012999426

Download citation: RISBibTeXText

PMID: 17130250

DOI: 10.1177/1087057106295897


Related references

Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metabolism and Disposition: the Biological Fate of Chemicals 35(7): 1232-1238, 2007

Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharmaceutical Research 29(7): 1960-1976, 2012

Drug-drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery. Drug Metabolism and Drug Interactions 21(3-4): 163-185, 2006

In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metabolism and Disposition: the Biological Fate of Chemicals 34(5): 786-792, 2006

Potential Metabolic Drug-Drug Interaction of Citrus aurantium L. ( Rutaceae ) Evaluating by Its Effect on 3 CYP450. Frontiers in Pharmacology 9: 895, 2018

Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 40(1): 24-37, 2010

Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. Journal of Pharmaceutical Sciences 100(9): 4013-4023, 2011

Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development. Drug Metabolism and Disposition: the Biological Fate of Chemicals 40(8): 1495-1507, 2012

Drug-Induced Phototoxicity; An Early In Vitro Identification of Phototoxic Potential of New Drug Entities in Drug Discovery and Development. Current Drug Safety 4(2): 123-136, 2009

Drug-induced phototoxicity; an early in vitro identification of phototoxic potential of new drug entities in drug discovery and development. Current Drug Safety 4(2): 123-136, 2009

Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chemico-Biological Interactions 121(1): 17-35, 1999

An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS. Biomedical Chromatography 30(10): 1556-1572, 2017

Mass Spectrometry Based Assays for Drug Screening in the Early Phases of Drug Discovery. Frontiers in Medicinal Chemistry - Online 1(1): 273-292, 2004

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus. Pharmaceutical Research 18(8): 1071-1080, 2001

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. British Journal of Clinical Pharmacology 52(1): 107-117, 2001